CTI BIOPHARMA CORP. CTIC Cash Flow

Cti biopharma corp. (CTIC)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
-12,186	-8,186	-10,047	-10,976	-10,814	845	-14,818	-11,344	-4,035	-14,270	-11,999	5,373	-19,935	-6,561	-29,361	-20,022	2,991	-26,016	-33,096	-32,766	-28,885	-41,914	4,360	-27,479	-29,196	9,970	-15,684	-18,220	-19,616	-18,714	-15,246	-50,198	-17,529	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Baxalta milestone revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	32,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-16,662	-16,997	-19,734
Equity-based compensation
1,200	1,289	1,293	1,318	1,300	1,496	2,528	1,040	1,336	1,397	1,355	1,149	1,799	2,099	5,068	2,331	3,826	1,831	5,888	2,773	4,336	3,174	3,837	5,356	7,829	2,742	1,928	1,968	2,428	1,854	1,016	3,085	1,983	2,697	780	996	544
Depreciation and amortization
133	134	136	136	140	152	146	150	152	159	159	189	193	195	194	210	232	233	245	251	261	225	259	256	360	393	390	406	411	601	659	565	521	663	698	606	444
Provision for Italian VAT receivables and deposit
4,200	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Write-off of deferred financing costs
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for bad debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-1	1,391	24	321	-176	176	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other-than-temporary impairment on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	1	0	0	519	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest expense
-	-	-	-	-	131	130	130	134	50	38	37	38	37	38	38	101	39	40	131	180	182	184	185	178	164	162	164	23	-	-	-	-	110	129	140	167
Noncash rent benefit
-	-	-	-	-	223	224	439	538	258	137	131	122	121	124	116	106	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	886	-187	219	-57	25	-	-	-	-	-	-	-	-
Noncontrolling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-65	-44	-70
Other
38	-134	-159	317	-215	-512	24	-306	0	-	-	-	-	-	-	-	-	-	-	102	93	337	92	90	-499	-220	16	90	-251	-200	-186	404	-23	1,716	90	23	129
Changes in operating assets and liabilities:
Receivables from license and development services arrangements
0	-	212	476	12,846	-	428	32	536	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	139	-73	-216	-250	-57	679	-302	-280	-436	-537	947	653	113	267	-298	-265	-1	791	-	-	-	-	-	-	-	-
Receivables from collaborative arrangements
-	-	-	-	-	-	-	-	-	-	-	126	-7,660	6,452	-3,544	6,568	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
-	-	-	-	-	-	-	-	-	-73	-907	-92	-48	-228	-70	-201	-68	912	-265	-120	-125	-190	-93	28	-50	1,259	254	991	750	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-1,038	-868	177	543	-972	849	-391	-194	-101	672	-196	-212	-590	402	-675	-3,340	2,004	-250	-540	253	939	805	-778	-212	139	1,219	-574	-1,270	-3,905	2,960	-2,114	2,757	156	-1,211	963	159	-478
Accounts payable, accrued expenses and other liabilities
-4,756	-	-	-	-8,072	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	56	87	-9	16	-10	-54	-15	-31	-39	-361	76	-55	427	21	-1,219	-397	387	-138	504	-11	212	257	388	-2,369	210	466	198	-152	6	-47	2,645
Accounts payable
-	-	-	-	-	-	-1,634	1,560	-419	534	-1,980	-7,919	4,635	-6,366	-385	-3,394	7,120	-2,751	2,143	645	4,331	70	38	1,756	-410	-5,011	-875	479	-367	916	-377	2,858	-274	25	-701	1,770	-1,404
Accrued expenses
-	-	-	-	-	-	1,423	-60	495	-1,120	-6,866	760	-3,870	1,984	5,860	-1,959	-3,265	4,930	-422	2,779	-4,861	4,144	3,656	2,382	68	1,634	-2,094	107	-481	1,010	585	569	-3,049	546	1,311	-101	-1,967
Deferred revenue
-	-	-	-	-	-	-365	-411	-189	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	1,139	176	-148	-486	-329	-108	-237	-353	-114	-214	-309	616	-195	-143	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	5	0	-5	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	1	0	-28	2	66	484	4,291	-313	-	-	-	-286
Total adjustments
-	-	-	-	-	-	-	-	-	-	-	-4,715	11,235	-8,008	16,136	-5,804	-26,051	3,934	8,903	7,841	4,882	45,763	-9,350	9,859	8,407	393	87	2,972	4,268	1,695	2,686	35,993	-1,463	3,558	539	2,932	-4,868
Net cash used in operating activities
-10,442	-11,486	-5,595	-7,285	-3,456	-12,649	-12,070	-12,682	-2,423	-10,502	-20,752	658	-8,700	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12,560	-14,205	-18,992	-5,668	-16,123	-14,065	-24,602
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-23,060	-	-24,193	-24,925	-24,003	3,849	-4,990	-17,620	-20,789	10,363	-15,597	-15,248	-15,348	-	-	-	-	-	-	-	-
Investing activities
Purchases of property and equipment
-	-	-	-	-	0	0	0	33	49	0	0	0	0	29	79	29	47	7	0	24	75	200	23	35	284	18	337	1,018	971	937	815	214	729	807	840	327
Proceeds from maturities of short-term investments
2,500	11,750	11,500	6,900	9,000	10,110	1,500	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sales of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	71	6	46	-	-	-	-	-	-	-	-
Net cash provided by investing activities
2,500	9,239	6,503	3,390	9,000	-2,545	-469	-27,443	-33	-49	0	11	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,619	-17,897	-214	-725	-780	-840	-327
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-29	-	-7	0	-24	-283	-200	-23	-35	-284	53	-331	-972	-	-	-	-	-	-	-	-
Financing activities
Proceeds from rights offering, net of issuance costs
59,280	0	0	0	0	0	0	-418	64,588	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of issuance costs from Silicon Valley Bank debt, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	73	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from debt, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-229	-34	9,764	-	-	-	-	-	-	-	-
Principal payments on debt
1,333	1,333	1,333	1,334	1,333	444	0	0	0	14,964	675	1,975	1,934	1,874	1,814	1,764	0	0	0	2,362	2,297	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of Stock Issuance Costs
0	230	0	0	45	168	5	93	2	-	-	-	-	-	-	-	135	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of tax withholding obligations related to restricted stock awards
-	-	-	-	-	1	1	18	1	-	-	-	-	44	7	191	113	24	36	17	527	11	59	3	105	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for repurchase of shares in connection with taxes on restricted stock vesting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35	101	206
Other
-	-	-	-	-	-	-	-	-	-	-13	-41	-38	9	1	21	-1	82	61	235	-213	219	2	87	-28	329	-47	-153	-126	105	-70	-162	-87	-401	-5,837	5,818	-4
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-249	-	15,685	35,539	-3,037	36,205	-57	84	-206	34,797	14,724	-187	9,638	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
57,947	-1,563	-1,333	-1,333	-1,378	-612	9	-491	64,585	986	-1,050	41,015	-1,972	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,928	18,768	-87	7,765	22,109	10,248	46,882
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-714	-	-138	-227	-47	-	-38	84	-203	-	6	-145	526	1,252	1,973	142	-8	-413	-572	20	560	-470	-215	709	-379	468	1,119	-270	-788
Net increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-21,940	41,457	-10,719	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
0	37	-22	-1	-12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
50,005	-3,773	-447	-5,229	4,154	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	61,415	-	-	-	-	-	-15,112	-27,934	-23,541	-	-8,509	10,469	-26,538	41,023	-3,274	-17,417	-21,038	44,463	-1,392	-15,746	-6,122	36,147	-466	-12,625	-19,672	1,840	6,325	-4,927	21,165
Supplemental disclosure of cash flow information
Cash paid during the period for interest
179	210	252	281	301	311	306	296	284	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid during the period for interest
-	-	-	-	-	-	-	-	-	-	-	509	551	598	674	702	2,472	560	547	436	524	511	472	472	439	315	316	297	5	6	3	2	5	320	4	699	2
Cash paid during the period for taxes
-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	0	0	-	0	0	0	0	0	0	0
Supplemental disclosure of noncash financing and investing activities
Right-of-use assets obtained in exchange for operating lease liabilities
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt issuance costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exchange of common stock and preferred stock for preferred stock
-	-	-	-	-	-	0	0	24,080	41,579	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issuance costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock upon exercise or exchange of common stock purchase warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,877	-	-	-	-	-	-	-	-	0	0	0	17,485
Baxalta milestone advance - earned in lieu of repayment
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	32,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of Series 8 and 10 preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	36,638